Prognostic Significance of the Systemic Immune-Inflammation Index (SII) in Patients With Small Cell Lung Cancer: A Meta-Analysis

Article Oncology

Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase

Qi Xiong et al.

Summary: In small cell lung cancer patients, NLR at 6 weeks after treatment initiation appears to be a biomarker of response to anti-PD-1/PD-L1 antibody treatment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Review Respiratory System

Update 2021: Management of Small Cell Lung Cancer

Sara Tariq et al.

Summary: SCLC accounts for 14% of lung cancer cases and is highly aggressive with limited treatment options. Recent advances have identified potential therapeutic targets and subtypes, but further research is needed to improve treatment outcomes.

LUNG (2021)

Add to Collection

Article Medicine, General & Internal

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

Edoardo Lenci et al.

Summary: The study found that GRImT1 and GRIm Delta are more reliable peripheral blood biomarkers of outcome compared to GRImT0 in aNSCLC patients, and may be useful in guiding clinical decisions.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Review Oncology

Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Gastric Cancer: A Meta-Analysis

Ye Qiu et al.

Summary: By conducting meta-analysis, this study found that a high pretreatment SII is associated with poor overall survival in gastric cancer patients and several clinical characteristics. Monitoring SII could be valuable for guiding prognostication in GC.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab

Wei-Xiang Qi et al.

Summary: Pre-treatment PLR could serve as an valuable independent prognostic factor for ES-SCLC patients treated with chemotherapy and immune checkpoint inhibitors, with high PLR values associated with significantly poorer survival outcomes.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Multidisciplinary Sciences

Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer

Sho Matsubara et al.

Summary: The study found that SII is an independent prognostic factor in endometrial cancer patients, allowing for more precise survival estimation compared to PLR or NLR.

PLOS ONE (2021)

Add to Collection

Article Cell Biology

Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients

Yifang Shui et al.

Aging-US (2021)

Add to Collection

Review Oncology

Small cell lung cancer: a slightly less orphan disease after immunotherapy

J. Remon et al.

Summary: Small cell lung cancer (SCLC) is an aggressive malignancy that has seen therapeutic advances with immune checkpoint inhibitors, but the benefit seems to be more modest compared to non-small cell lung cancer. The immunosuppressive phenotype of SCLC may explain the differences in outcomes between these two types of lung cancer. Challenges ahead include applying immunotherapeutic strategies in elderly patients, those with poor performance status, or brain metastases.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer

Hiroyuki Inoue et al.

Summary: This study demonstrates that a preoperative systemic immune-inflammation index (SII) higher than 395 may be associated with poor postoperative survival outcomes and increased risk of peritoneal recurrence in gastric cancer patients.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer

Satoshi Katayama et al.

Summary: The study assessed the prognostic value of systemic immune-inflammation index (SII) in non-muscle-invasive bladder cancer (NMIBC) patients, finding that high SII was significantly associated with worse progression-free survival and cancer-specific survival. Adding SII to the standard predictive model improved its discrimination ability.

WORLD JOURNAL OF UROLOGY (2021)

Add to Collection

Article Oncology

Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

Zanzan Wang et al.

Summary: The study evaluated the role of systemic immune-inflammation index (SII) in predicting survival for patients with diffuse large B cell lymphoma (DLBCL). SII was found to be a powerful prognostic tool, with higher SII values indicating poorer prognosis and potentially aiding in identifying high-risk patients among those with the same international prognostic index (IPI).

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer

Jing-hao Yao et al.

Summary: The study aimed to evaluate the diagnostic and predictive values of serum VEGF-A level and SII in SCLC patients. Results showed that VEGF-A is closely associated with chemotherapeutic efficacy and prognosis, serving as an independent prognostic factor in SCLC patients.

JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology